Purple Biotech (PPBT) Cash from Investing Activities (2017 - 2026)
Purple Biotech (PPBT) reported Cash from Investing Activities of $45000.0 for Q1 2026, down 82.49% year-over-year from $257000.0 in Q1 2025, and up 143.27% quarter-over-quarter from -$104000.0 in Q4 2025.
Purple Biotech (PPBT) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Cash from Investing Activities data on file, last reported at $45000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $45000.0, down 82.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $420000.0 (down 7.49% YoY), and the FY2025 annual result was $632000.0, up 24.17% from the prior year.
- Cash from Investing Activities improved to $45000.0 in Q1 2026 per PPBT's latest filing, from -$104000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $17.7 million in Q1 2022 and troughed at -$6.0 million in Q2 2022.
- A 5-year average of $2.1 million and a median of $177000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities soared 1249.28% in 2022, then sank 373.68% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at $8.0 million in 2022, then sank by 99.07% to $74000.0 in 2023, then plunged by 48.65% to $38000.0 in 2024, then plunged by 373.68% to -$104000.0 in 2025, then surged by 143.27% to $45000.0 in 2026.
- Business Quant data shows PPBT's Cash from Investing Activities at $45000.0 in Q1 2026, -$104000.0 in Q4 2025, and $372000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | 45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45,000.00 |
| Mar 31, 2026 | 45,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Mar 31, 2025 | 257,000.00 |
| Mar 31, 2025 | 257,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 72,000.00 |
| Sep 30, 2024 | 72,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 312,000.00 |
| Mar 31, 2024 | 312,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Dec 31, 2023 | 74,000.00 |